Alireza Esteghamati

List of Publications by Year
in descending order

237 papers	78,353 citations	23567 58 h-index	1347 223 g-index
242 all docs	242 docs citations	242 times ranked	111310 citing authors

#	Article	IF	Citations
1	Global, regional, and national prevalence of overweight and obesity in children and adults during 1980â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 766-781.	13.7	9,122
2	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	13.7	5,578
3	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine, 2017, 377, 13-27.	27.0	5,014
4	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	13.7	4,951
5	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	13.7	4,934
6	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	13.7	4,203
7	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	13.7	3,565
8	Health effects of dietary risks in 195 countries, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2019, 393, 1958-1972.	13.7	3,062
9	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	13.7	2,858
10	Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. Journal of the American College of Cardiology, 2017, 70, 1-25.	2.8	2,705
11	Global, regional, and national burden of neurological disorders, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	10.2	2,625
12	The Global Burden of Cancer 2013. JAMA Oncology, 2015, 1, 505.	7.1	2,269
13	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	13.7	2,184
14	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	13.7	2,123
15	Alcohol use and burden for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2018, 392, 1015-1035.	13.7	2,005
16	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1345-1422.	13.7	1,879
17	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	13.7	1,612
18	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	13.7	1,589

#	Article	IF	Citations
19	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990â€“2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	13.7	1,544
20	Global, regional, and national levels and causes of maternal mortality during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 980-1004.	13.7	1,230
21	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 56-87.	10.2	1,064
22	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 1005-1070.	13.7	786
23	Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	13.7	740
24	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	13.7	573
25	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	13.7	571
26	Global and regional estimates and projections of diabetes-related health expenditure: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice, 2020, 162, 108072.	2.8	501
27	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	13.7	480
28	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	4.7	461
29	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	13.7	413
30	The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2019, 4, 934-947.	8.1	372
31	Five insights from the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1135-1159.	13.7	335
32	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1250-1284.	13.7	330
33	Prevalence of Diabetes and Impaired Fasting Glucose in the Adult Population of Iran: National Survey of Risk Factors for Non-Communicable Diseases of Iran. Diabetes Care, 2008, 31, 96-98.	8.6	295
34	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	13.7	284
35	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2019, 4, 913-933.	8.1	259
36	Third national surveillance of risk factors of non-communicable diseases (SuRFNCD-2007) in Iran: methods and results on prevalence of diabetes, hypertension, obesity, central obesity, and dyslipidemia. BMC Public Health, 2009, 9, 167.	2.9	256

#	Article	IF	Citations
37	Global, Regional, and National Burden of Calcific Aortic Valve and Degenerative Mitral Valve Diseases, 1990â€“2017. Circulation, 2020, 141, 1670-1680.	1.6	206
38	Diabetes in Iran: Prospective Analysis from First Nationwide Diabetes Report of National Program for Prevention and Control of Diabetes (NPPCD-2016). Scientific Reports, 2017, 7, 13461.	3.3	201
39	Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005â€“2011. Diabetes Research and Clinical Practice, 2014, 103, 319-327.	2.8	197
40	Global Mortality From Firearms, 1990-2016. JAMA - Journal of the American Medical Association, 2018, 320, 792.	7.4	189
41	Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: A randomized clinical trial. Clinical Nutrition, 2013, 32, 179-185.	5.0	167
42	Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas, 2010, 65, 262-266.	2.4	153
43	Health in times of uncertainty in the eastern Mediterranean region, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet Global Health, 2016, 4, e704-e713.	6.3	147
44	Pattern of tobacco use among the Iranian adult population: results of the national Survey of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007). Tobacco Control, 2010, 19, 125-128.	3.2	146
45	Appropriate definition of metabolic syndrome among Iranian adults: report of the Iranian National Committee of Obesity. Archives of Iranian Medicine, 2010, 13, 426-8.	0.6	146
46	Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutrition and Metabolism, 2010, 7, 26.	3.0	143
47	The urgent need for integrated science to fight COVID-19 pandemic and beyond. Journal of Translational Medicine, 2020, 18, 205.	4.4	128
48	Prevalence, Awareness, Treatment, and Risk Factors Associated With Hypertension in the Iranian Population: The National Survey of Risk Factors for Noncommunicable Diseases of Iran. American Journal of Hypertension, 2008, 21, 620-626.	2.0	124
49	Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity. Archives of Iranian Medicine, 2010, 13, 243-4.	0.6	112
50	Prevalence, awareness and risk factors of hypertension in a large cohort of Iranian adult population. Journal of Hypertension, 2013, 31, 1364-1371.	0.5	110
51	Increased serum HSP70 levels are associated with the duration of diabetes. Cell Stress and Chaperones, 2010, 15, 959-964.	2.9	99
52	Physical Activity in Iran: Results of the Third National Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007). Journal of Physical Activity and Health, 2011, 8, 27-35.	2.0	94
53	Waist circumference cut-off points for the diagnosis of metabolic syndrome in Iranian adults. Diabetes Research and Clinical Practice, 2008, 82, 104-107.	2.8	74
54	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000â€“17: analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 1779-1801.	13.7	72

#	Article	IF	Citations
55	Secular Trends of Obesity in Iran Between 1999 and 2007: National Surveys of Risk Factors of Non-Communicable Diseases. Metabolic Syndrome and Related Disorders, 2010, 8, 209-213.	1.3	71
56	Complementary and Alternative Medicine for the Treatment of Obesity: A Critical Review. International Journal of Endocrinology and Metabolism, 2015, 13, e19678.	1.0	67
57	Serum Oxidizedâ€LDL is Associated with Diabetes Duration Independent of Maintaining Optimized Levels of LDLâ€Cholesterol. Lipids, 2010, 45, 321-327.	1.7	66
58	Prevalence of diabetes and other cardiovascular risk factors in an Iranian population with acute coronary syndrome. Cardiovascular Diabetology, 2006, 5, 15.	6.8	62
59	Diabetes Care in Iran: Where We Stand and Where We Are Headed. Annals of Global Health, 2018, 81, 839.	2.0	62
60	Optimal threshold of homeostasis model assessment for insulin resistance in an Iranian population: The implication of metabolic syndrome to detect insulin resistance. Diabetes Research and Clinical Practice, 2009, 84, 279-287.	2.8	57
61	Gender-specific changes in physical activity pattern in Iran: national surveillance of risk factors of non-communicable diseases (2007â€"2011). International Journal of Public Health, 2014, 59, 231-241.	2.3	52
62	Association of Serum Leptin Levels With Homeostasis Model Assessmentâ€"Estimated Insulin Resistance and Metabolic Syndrome: The Key Role of Central Obesity. Metabolic Syndrome and Related Disorders, 2009, 7, 447-452.	1.3	51
63	Patterns of fruit and vegetable consumption among Iranian adults: a SuRFNCD-2007 study. British Journal of Nutrition, 2012, 108, 177-181.	2.3	49
64	Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Research and Clinical Practice, 2011, 91, 154-158.	2.8	46
65	Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrology Dialysis Transplantation, 2013, 28, 2823-2833.	0.7	46
66	Differences in vitamin D concentration between metabolically healthy and unhealthy obese adults: Associations with inflammatory and cardiometabolic markers in 4391 subjects. Diabetes and Metabolism, 2014, 40, 347-355.	2.9	45
67	An inverse association between serum vitamin D levels with the presence and severity of impaired nerve conduction velocity and large fiber peripheral neuropathy in diabetic subjects. Neurological Sciences, 2015, 36, 1121-1126.	1.9	44
68	The effects of a Melissa officinalis L. based product on metabolic parameters in patients with type 2 diabetes mellitus: A randomized double-blinded controlled clinical trial. Journal of Complementary and Integrative Medicine, 2019, 16, .	0.9	44
69	Metabolic Syndrome and Insulin Resistance Significantly Correlate with Body Mass Index. Archives of Medical Research, 2008, 39, 803-808.	3.3	43
70	Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects. American Journal of Men's Health, 2017, 11, 426-434.	1.6	42
71	Inflammatory, oxidative stress and anti-oxidative markers in patients with endometrial carcinoma and diabetes. Cytokine, 2019, 120, 186-190.	3.2	42
72	Comparative effects of pioglitazone and metformin on oxidative stress markers in newly diagnosed type 2 diabetes patients: A randomized clinical trial. Journal of Diabetes and Its Complications, 2013, 27, 501-507.	2.3	41

#	Article	IF	Citations
73	Association of Depression and Anxiety With Diabetes Mellitus Type 2 Concerning Some Sociological Factors. Iranian Red Crescent Medical Journal, 2013, 15, 644-648.	0.5	37
74	Assessment of serum 25-hydroxy vitamin D improves coronary heart disease risk stratification in patients with type 2 diabetes. American Heart Journal, 2015, 170, 573-579.e5.	2.7	35
75	Raised serum 25-hydroxyvitamin D levels in patients with active diabetic foot ulcers. British Journal of Nutrition, 2016, 115, 1938-1946.	2.3	35
76	Homocysteine and metabolic syndrome: From clustering to additional utility in prediction of coronary heart disease. Journal of Cardiology, 2014, 64, 290-296.	1.9	33
77	Prevalence of metabolic syndrome in Iran: A 2011 update. Journal of Diabetes, 2017, 9, 518-525.	1.8	33
78	Neutrophil Gelatinase-Associated Lipocalin and Retinol-Binding Protein-4 as Biomarkers for Diabetic Kidney Disease. Kidney and Blood Pressure Research, 2020, 45, 222-232.	2.0	33
79	Association of +45(T/G) and +276(G/T) polymorphisms in the adiponectin gene with coronary artery disease in a population of Iranian patients with type 2 diabetes. Molecular Biology Reports, 2012, 39, 3791-3797.	2.3	32
80	Awareness, Treatment and Control of Pre-hypertension and Hypertension among Adults in Iran. Archives of Iranian Medicine, 2016, 19, 456-64.	0.6	31
81	Association between physical activity and metabolic syndrome in Iranian adults: national surveillance of risk factors of noncommunicable diseases (SuRFNCD-2007). Metabolism: Clinical and Experimental, 2009, 58, 1347-1355.	3.4	30
82	The cost of diabetes chronic complications among Iranian people with type 2 diabetes mellitus. Journal of Diabetes and Metabolic Disorders, 2014, 13, 42.	1.9	30
83	Type 2 Diabetes: Model of Factors Associated with Glycemic Control. Canadian Journal of Diabetes, 2016, 40, 424-430.	0.8	30
84	Association between physical activity and insulin resistance in Iranian adults: National Surveillance of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007). Preventive Medicine, 2009, 49, 402-406.	3.4	29
85	Clustering of metabolic syndrome components in a Middle Eastern diabetic and non-diabetic population. Diabetology and Metabolic Syndrome, 2010, 2, 36.	2.7	29
86	Baseline High-Sensitivity C-Reactive Protein Predicts Macrovascular and Microvascular Complications of Type 2 Diabetes: A Population-Based Study. Annals of Nutrition and Metabolism, 2018, 72, 287-295.	1.9	29
87	Response-oriented measuring inequalities in Tehran: second round of UrbanHealth Equity Assessment and Response Tool (Urban HEART-2), concepts and framework. Medical Journal of the Islamic Republic of Iran, 2013, 27, 236-48.	0.9	29
88	Contribution of Serum Leptin to Metabolic Syndrome in Obese andÂNonobeseÂSubjects. Archives of Medical Research, 2011, 42, 244-251.	3.3	28
89	Evaluation of plasma MMP-8, MMP-9 and TIMP-1 identifies candidate cardiometabolic risk marker in metabolic syndrome: results from double-blinded nested caseâ€"control study. Metabolism: Clinical and Experimental, 2015, 64, 527-538.	3.4	28
90	The dual behavior of heat shock protein 70 and asymmetric dimethylarginine in relation to serum CRP levels in type 2 diabetes. Gene, 2012, 498, 107-111.	2.2	27

#	Article	IF	Citations
91	Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. International Journal of Endocrinology and Metabolism, 2019, In Press, e84353.	1.0	27
92	Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. Diabetology and Metabolic Syndrome, 2010, 2, 65.	2.7	26
93	Serum heat shock protein 70 and oxidized LDL in patients with type 2 diabetes: does sex matter?. Cell Stress and Chaperones, 2011, 16, 195-201.	2.9	26
94	Association of CTLA-4 gene polymorphism with Graves' disease and ophthalmopathy in Iranian patients. European Journal of Internal Medicine, 2009, 20, 424-428.	2.2	25
95	Gravesâ€™ disease and gene polymorphism of TNF-Î±, IL-2, IL-6, IL-12, and IFN-Î³. Endocrine, 2010, 37, 344-348.	2.3	25
96	Association of Vaspin with Metabolic Syndrome: The Pivotal Role of Insulin Resistance. Diabetes and Metabolism Journal, 2014, 38, 143.	4.7	25
97	Metabolic syndrome in premenopausal and postmenopausal women with type 2 diabetes: loss of protective effects of premenopausal status. Journal of Diabetes and Metabolic Disorders, 2014, 13, 102.	1.9	25
98	Lipoprotein(a) and Apolipoproteins as Predictors for Diabetic Retinopathy and Its Severity in Adults With Type 2 Diabetes: A Case-Cohort Study. Canadian Journal of Diabetes, 2020, 44, 414-421.	0.8	25
99	Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Regulatory Peptides, 2013, 182, 1-6.	1.9	24
100	Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in type 2 diabetes. Atherosclerosis, 2016, 254, 42-51.	0.8	24
101	Ambulatory blood pressure monitoring and diabetes complications. Medicine (United States), 2018, 97, e12185.	1.0	24
102	Waist-To-Height Ratio Is a More Accurate Tool for Predicting Hypertension Than Waist-To-Hip Circumference and BMI in Patients With Type 2 Diabetes: A Prospective Study. Frontiers in Public Health, 2021, 9, 726288.	2.7	24
103	Oxidized Low-Density Lipoprotein Is Negatively Correlated With Lecithin-Cholesterol Acyltransferase Activity in Type 2 Diabetes Mellitus. American Journal of the Medical Sciences, 2011, 341, 92-95.	1.1	23
104	Heat shock protein 70 and albuminuria in patients with type 2 diabetes: a matched case control study. Cell Stress and Chaperones, 2013, 18, 815-819.	2.9	23
105	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000â€“17. The Lancet Global Health, 2020, 8, e1038-e1060.	6.3	23
106	Serum Uric Acid, the Metabolic Syndrome, and the Risk of Chronic Kidney Disease in Patients with Type 2 Diabetes. Metabolic Syndrome and Related Disorders, 2014, 12, 102-109.	1.3	22
107	Circulating levels of fibroblast growth factor 21 in early-stage diabetic kidney disease. Irish Journal of Medical Science, 2017, 186, 785-794.	1.5	22
108	Patient and physician preferences for type 2 diabetes medications: a systematic review. Journal of Diabetes and Metabolic Disorders, 2019, 18, 643-656.	1.9	22

#	Article	IF	Citations
109	Effects of zinc, vitamin D, and their co-supplementation on mood, serum cortisol, and brain-derived neurotrophic factor in patients with obesity and mild to moderate depressive symptoms: A phase II, 12-wk, 2â€¯Ã—â€¯2 factorial design, double-blind, randomized, placebo-controlled trial. Nutrition, 2020, 71, 110601.	2.4	22
110	Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes. Archives of Cardiovascular Diseases, 2015, 108, 412-419.	1.6	21
111	Contribution of vitamin D deficiency to the risk of coronary heart disease in subjects with essential hypertension. Atherosclerosis, 2016, 244, 165-171.	0.8	21
112	Lp(a) and Apo-lipoproteins as predictors for micro- and macrovascular complications of diabetes: A case-cohort study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1723-1731.	2.6	21
113	Effects of a Mediterranean diet on the development of diabetic complications: A longitudinal study from the nationwide diabetes report of the National Program for Prevention and Control of Diabetes (NPPCD 2016-2020). Maturitas, 2021, 153, 61-67.	2.4	21
114	Insulin Resistance Is Independently Associated with Liver Aminotransferases in Diabetic Patients Without Ultrasound Signs of Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders, 2011, 9, 111-117.	1.3	20
115	Appearance of leptinâ€"HSP70 correlation, in type 2 diabetes. Meta Gene, 2013, 1, 1-7.	0.6	20
116	Pioglitazone and metformin are equally effective in reduction of chemerin in patients with typeÂ2 diabetes. Journal of Diabetes Investigation, 2014, 5, 327-332.	2.4	20
117	The Prevalence of Metabolic Syndrome and Different Obesity Phenotype in Iranian Male Military Personnel. American Journal of Men's Health, 2017, 11, 404-413.	1.6	20
118	Intercellular adhesion molecule-1 in diabetic patients with and without microalbuminuria. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 365-368.	3.6	20
119	Association of non-alcoholic fatty liver disease with microvascular complications of type 2 diabetes. Primary Care Diabetes, 2019, 13, 505-514.	1.8	20
120	The Value of Visfatin in the Prediction of Metabolic Syndrome: A Multi-Factorial Analysis. Journal of Cardiovascular Translational Research, 2012, 5, 541-546.	2.4	19
121	Association Of Peripheral 5-Hydroxyindole-3-Acetic Acid, A Serotonin Derivative, with Metabolic Syndrome and Low-Grade Inflammation. Endocrine Practice, 2015, 21, 711-718.	2.1	19
122	Serum fibroblast growth factor 21 concentrations in type 2 diabetic retinopathy patients. Annales D'Endocrinologie, 2016, 77, 586-592.	1.4	19
123	Advanced glycation end-products and advanced oxidation protein products levels are correlates of duration of type 2 diabetes. Life Sciences, 2020, 260, 118422.	4.3	19
124	Nitric oxide and TNF-Î± are correlates of diabetic retinopathy independent of hs-CRP and HbA1c. Endocrine, 2020, 69, 536-541.	2.3	19
125	Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes. Translational Research, 2011, 158, 85-91.	5.0	18
126	Physical Inactivity Is Correlated with Levels of Quantitative C-reactive Protein in Serum, Independent of Obesity: Results of the National Surveillance of Risk Factors of Non-communicable Diseases in Iran. Journal of Health, Population and Nutrition, 2012, 30, 66-72.	2.0	18

#	Article	IF	Citations
127	Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2015, 9, 258-265.	3.6	18
128	Non-linear contribution of serum vitamin D to symptomatic diabetic neuropathy: A case-control study. Diabetes Research and Clinical Practice, 2016, 111, 44-50.	2.8	18
129	National Prevalence of Self-Reported Coronary Heart Disease and Chronic Stable Angina Pectoris: Factor Analysis of the Underlying Cardiometabolic Risk Factors in the SuRFNCD-2011. Global Heart, 2018, 13, 73.	2.3	18
130	CA 19-9 is Associated with Poor Glycemic Control in Diabetic Patients: Role of Insulin Resistance. Clinical Laboratory, 2014, 60, 441-7.	0.5	18
131	Metabolic syndrome is independently associated with microalbuminuria in type 2 diabetes. Acta Diabetologica, 2010, 47, 125-130.	2.5	17
132	Physical activity is correlated with serum leptin independent of obesity: results of the national surveillance of risk factors of noncommunicable diseases in Iran (SuRFNCD-2007). Metabolism: Clinical and Experimental, 2010, 59, 1730-1735.	3.4	16
133	LDL/apo B ratio predict coronary heart disease in Type 2 diabetes independent of ASCVD risk score: A case-cohort study. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1477-1485.	2.6	16
134	Nonâ€"high-density lipoprotein fractions are strongly associated with the presence of metabolic syndrome independent of obesity and diabetes: a population-based study among Iranian adults. Journal of Diabetes and Metabolic Disorders, 2017, 16, 25.	1.9	15
135	Insulin pen use and diabetes treatment goals: A study from Iran STEPS 2016 survey. PLoS ONE, 2019, 14, e0221462.	2.5	15
136	Association of extracellular heat shock protein 70 and insulin resistance in type 2 diabetes; independent of obesity and C-reactive protein. Cell Stress and Chaperones, 2019, 24, 69-75.	2.9	15
137	Association between dietary inflammatory index and components of metabolic syndrome. Journal of Cardiovascular and Thoracic Research, 2020, 12, 27-34.	0.9	15
138	Leptin cut-off values for determination of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Endocrine, 2011, 40, 117-123.	2.3	14
139	Gender Difference in Albuminuria and Ischemic Heart Disease in Type 2 Diabetes. Clinical Medicine and Research, 2012, 10, 51-56.	0.8	14
140	Associations of Serum S100B and S100P With the Presence and Classification of Diabetic Peripheral Neuropathy in Adults With Type 2 Diabetes: A Case-Cohort Study. Canadian Journal of Diabetes, 2019, 43, 336-344.e2.	0.8	14
141	Smoking and Diabetes Control in Adults With Type 1 and Type 2 Diabetes: A Nationwide Study From the 2018 National Program for Prevention and Control of Diabetes of Iran. Canadian Journal of Diabetes, 2020, 44, 246-252.	0.8	14
142	Clustering of leptin and physical activity with components of metabolic syndrome in Iranian population: an exploratory factor analysis. Endocrine, 2010, 38, 206-213.	2.3	13
143	Epidemiology and risk factors of the cardiometabolic syndrome in the Middle East. Expert Review of Cardiovascular Therapy, 2011, 9, 309-320.	1.5	13
144	Metformin restores the correlation between serum-oxidized LDL and leptin levels in type 2 diabetic patients. Redox Report, 2011, 16, 193-200.	4.5	13

#	Article	IF	Citations
145	Risk of coronary heart disease associated with metabolic syndrome and its individual components in Iranian subjects: A matched cohort study. Journal of Clinical Lipidology, 2014, 8, 279-286.	1.5	13
146	Abdominal obesity and gestational diabetes: the interactive role of magnesium. Magnesium Research, 2015, 28, 116-125.	0.5	13
147	Nonlinear relation between pulse pressure and coronary heart disease in patients with type 2 diabetes or hypertension. Journal of Hypertension, 2016, 34, 974-980.	0.5	13
148	Fasting hyperinsulinaemia and 2-h glycaemia predict coronary heart disease in patients with type 2 diabetes. Diabetes and Metabolism, 2016, 42, 55-61.	2.9	13
149	Association of serum cortisol levels with parameters of metabolic syndrome in men and women. Clinical and Investigative Medicine, 2011, 34, 131.	0.6	13
150	Oxidized Low-Density Lipoprotein (ox-LDL) to LDL Ratio (ox-LDL/LDL) and ox-LDL to High-Density Lipoprotein Ratio (ox-LDL/HDL):. Clinical Laboratory, 2016, 62, 1609-1617.	0.5	13
151	HOMA-Estimated Insulin Resistance Is Associated with Hypertension in Iranian Diabetic and Non-Diabetic Subjects. Clinical and Experimental Hypertension, 2008, 30, 297-307.	1.3	12
152	Association of oxidized low-density lipoprotein and transforming growth factor-beta in type 2 diabetic patients: a cross-sectional study. Translational Research, 2009, 153, 86-90.	5.0	12
153	Association of plasma leptin levels and insulin resistance in diabetic women: a cross-sectional analysis in an Iranian population with different results in men and women. Gynecological Endocrinology, 2011, 27, 14-19.	1.7	12
154	Cardiovascular risk assessment by FRS and SCORE in Iranian adult population. Journal of Diabetes and Metabolic Disorders, 2017, 16, 35.	1.9	12
155	Beneficial Effects of Pentoxifylline Plus Losartan Dual Therapy in Type 2 Diabetes with Nephropathy. American Journal of the Medical Sciences, 2018, 355, 442-448.	1.1	12
156	Determinants of glycemic control: Phase 2 analysis from nationwide diabetes report of National Program for Prevention and Control of Diabetes (NPPCD-2018). Primary Care Diabetes, 2020, 14, 222-231.	1.8	12
157	All-Cause and Cardiovascular Mortality following Treatment with Metformin or Glyburide in Patients with Type 2 Diabetes Mellitus. Archives of Iranian Medicine, 2017, 20, 141-146.	0.6	12
158	Association of macroalbuminuria with oxidized LDL and TGF-Î² in type 2 diabetic patients: a caseâ€“control study. International Urology and Nephrology, 2010, 42, 487-492.	1.4	10
159	Accuracy of Anthropometric Parameters in Identification of High-risk Patients Predicted With Cardiovascular Risk Models. American Journal of the Medical Sciences, 2013, 346, 26-31.	1.1	10
160	Conflicting interactions of apolipoprotein A and high density lipoprotein cholesterol with microvascular complications of type 2 diabetes. Diabetes Research and Clinical Practice, 2017, 133, 131-141.	2.8	10
161	The Role of Metabolic Syndrome and Related Clinical Variables in Determining CEA Levels. Advances in Clinical and Experimental Medicine, 2014, 23, 907-912.	1.4	10
162	Association between oxidant/antioxidant markers and proteinuria in type 2 diabetes: results in 142 patients. Journal of Nephrology, 2009, 22, 733-8.	2.0	10

#	Article	IF	Citations
163	Family history of diabetes and the risk of coronary heart disease in people with or without type 2 diabetes. Diabetes and Metabolism, 2017, 43, 180-183.	2.9	9
164	Inverse Association of Peripheral Orexin-A with Insulin Resistance in Type 2 Diabetes Mellitus: A Randomized Clinical Trial. Review of Diabetic Studies, 2017, 14, 301-310.	1.3	9
165	Prostaglandin F2 Alpha Plasma Concentration Predicts Glycemic Control and Oxidation Status in Patients with Type 2 Diabetes Mellitus. Clinical Laboratory, 2014, 60, 2073-80.	0.5	9
166	Obesity and Diabetic Complications: A Study from the Nationwide Diabetes Report of the National Program for Prevention and Control of Diabetes (NPPCD-2021) Implications for Action on Multiple Scales. Primary Care Diabetes, 2022, 16, 422-429.	1.8	9
167	Appropriate BMI cut-off values for identification of metabolic risk factors: Third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Annals of Human Biology, 2012, 39, 484-489.	1.0	8
168	Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial. Journal of Endocrinological Investigation, 2014, 37, 1211-1218.	3.3	8
169	Polymorphism of killer cell immunoglobulin-like receptors (KIR) and their HLA ligands in Gravesâ€™ disease. Molecular Biology Reports, 2014, 41, 5367-5374.	2.3	8
170	Serum 25-hydroxyvitamin D, non-alcoholic fatty liver disease and type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 93-95.	2.6	8
171	Evaluating the effect of type 2 diabetes mellitus on CYP450 enzymes and P-gp activities, before and after glycemic control: A protocol for a caseâ€“control pharmacokinetic study. MethodsX, 2020, 7, 100853.	1.6	8
172	Uncontrolled hypertension in patients with type 2 diabetes: What are the correlates?. Journal of Clinical Hypertension, 2021, 23, 1776-1785.	2.0	8
173	Core components of clinical education: a qualitative study with attending physicians and their residents. Journal of Advances in Medical Education and Professionalism, 2016, 4, 64-71.	0.2	8
174	The lost correlation between leptin and CRP in type 2 diabetes. European Cytokine Network, 2013, 24, 53-59.	2.0	7
175	Manual or Automated Sphygmomanometer? A Historical Cohort to Quantify Measurement Bias in Blood Pressure Recording. Journal of Clinical Hypertension, 2014, 16, 716-721.	2.0	7
176	Comment on Fischer et al. Text Message Support for Weight Loss in Patients With Prediabetes: A Randomized Clinical Trial. Diabetes Care 2016;39:1364â€“1370. Diabetes Care, 2016, 39, e206-e206.	8.6	7
177	Association of peripheral nesfatin-1 with early stage diabetic nephropathy. Pathophysiology, 2017, 24, 17-22.	2.2	7
178	Comparison of primary versus secondary prevention of cardiovascular disease in patients with type2 diabetes: Focus on achievement of ABC goals. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1733-1737.	3.6	7
179	Improvement in Redox Homeostasis after Cytoreductive Surgery in Colorectal Adenocarcinoma. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-12.	4.0	7
180	Diet quality in obese/overweight individuals with/without metabolic syndrome compared to normal weight controls. Medical Journal of the Islamic Republic of Iran, 2016, 30, 376.	0.9	7

#	Article	IF	Citations
181	Albuminuria and its correlates in an Iranian type 2 diabetic population. Lipids in Health and Disease, 2008, 7, 28.	3.0	6
182	The Inverse Relation of CA-125 to Diabetes, Metabolic Syndrome, and Associated Clinical Variables. Metabolic Syndrome and Related Disorders, 2013, 11, 256-261.	1.3	6
183	Absence of a positive correlation between CRP and leptin in rheumatoid arthritis. Heliyon, 2016, 2, e00205.	3.2	6
184	Comparing serum concentration of spexin among patients with metabolic syndrome, healthy overweight/obese, and normal-weight individuals. Medical Journal of the Islamic Republic of Iran, 2019, 33, 93.	0.9	6
185	Insulin Resistance and Breast Carcinogenesis: A Cross-Sectional Study Among Iranian Women with Breast Mass. Metabolic Syndrome and Related Disorders, 2010, 8, 411-416.	1.3	5
186	Treatment with pioglitazone is associated with decreased preprandial ghrelin levels: A randomized clinical trial. Peptides, 2013, 40, 89-92.	2.4	5
187	The Degree of Resistance of Erythrocyte Membrane Cytoskeletal Proteins to Supra-Physiologic Concentrations of Calcium: An In Vitro Study. Journal of Membrane Biology, 2014, 247, 695-701.	2.1	5
188	Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study. BMC Endocrine Disorders, 2016, 16, 35.	2.2	5
189	Pulse pressure and diabetes treatments. Medicine (United States), 2018, 97, e9791.	1.0	5
190	Role of type 2 diabetes and hemodialysis in serum adipolin concentrations: A preliminary study. Hemodialysis International, 2019, 23, 472-478.	0.9	5
191	DPP4 Inhibitors in the Management of Hospitalized Patients With TypeÂ2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Advances in Therapy, 2020, 37, 3660-3675.	2.9	5
192	Depressive symptoms among metabolically healthy and unhealthy overweight/obese individuals: a comparative study. Medical Journal of the Islamic Republic of Iran, 2018, 32, 549-552.	0.9	5
193	Diabetes Management during the COVID-19 Pandemic: An Iranian Expert Opinion Statement. Archives of Iranian Medicine, 2020, 23, 564-567.	0.6	5
194	Adiponectin: An Indicator for Metabolic Syndrome. Iranian Journal of Public Health, 2019, 48, 1106-1115.	0.5	5
195	Distributions of High-Sensitivity C-Reactive Protein, Total Cholesterol-HDL Ratio and 10-Year Cardiovascular Risk: National Population-Based Study. Acta Medica Iranica, 2017, 55, 218-227.	0.8	5
196	Response: Association of Vaspin with Metabolic Syndrome: The Pivotal Role of Insulin Resistance (Diabetes Metab J2014;38:143-9). Diabetes and Metabolism Journal, 2014, 38, 242.	4.7	4
197	Associations of small dense low-density lipoprotein and adiponectin with complications of type 2 diabetes. Endocrine Research, 2015, 40, 14-19.	1.2	4
198	The lost correlation between heat shock protein 70 (HSPA1A) and plasminogen activator inhibitor-1 in patients with type 2 diabetes and albuminuria. Cell Stress and Chaperones, 2016, 21, 361-365.	2.9	4

#	Article	IF	Citations
199	Serum HSP70 level in patients with endometrial cancer with and without diabetes. Gynecological Endocrinology, 2020, 36, 351-355.	1.7	4
200	Prevalence of diabetes-associated autoantibodies among patients presenting with type 2 diabetes and related metabolic differences. Primary Care Diabetes, 2021, 15, 169-174.	1.8	4
201	COVID-19 infection mortality risk in Iranian patients with type 2 diabetes, hypertension and obesity. Eastern Mediterranean Health Journal, 2022, 28, 221-224.	0.8	4
202	Clinical Lipid Control Success Rate Before and After Percutaneous Coronary Intervention in Iran; a Single Center Study. Iranian Red Crescent Medical Journal, 2013, 15, 467-72.	0.5	4
203	The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study--the Iran subgroup of the IMPROVEâ„¢ study. Endokrynologia Polska, 2010, 61, 364-70.	1.0	4
204	Effect of daily consumption of probiotic yoghurt on albumin to creatinine ratio, eGFR and metabolic parameters in patients with type 2 diabetes with microalbuminuria: study protocol for a randomised controlled clinical trial. BMJ Open, 2022, 12, e056110.	1.9	4
205	Comparing Abilities of Different Lipid Measures in Diagnosis of Insulin Resistance: A Survey of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007) Study. Metabolic Syndrome and Related Disorders, 2012, 10, 63-69.	1.3	3
206	Revising the fasting glucose threshold for detection of cardiovascular risk factors: analysing two representative population-based studies of more than 50â€‰000 Iranians in 3 years: The National Survey of Risk Factors for Non-Communicable Diseases of Iran. Annals of Human Biology, 2015, 42, 151-159.	1.0	3
207	Definition of an oxidative stress status by combined assessment of Malondialdehyde and Oxidized-LDL: A study in patients with type2 diabetes and control. Meta Gene, 2019, 19, 91-97.	0.6	3
208	Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea. Journal of Endocrinological Investigation, 2019, 42, 851-857.	3.3	3
209	Iranian National Clinical Practice Guideline for Exercise in Patients with Diabetes. International Journal of Endocrinology and Metabolism, 2021, 19, e109021.	1.0	3
210	Type 1 diabetic manifestations in a young man triggered by COVIDâ€19. Clinical Case Reports (discontinued), 2021, 9, e04211.	0.5	3
211	Barriers to initiation of insulin therapy in poorly controlled type 2 diabetes based on self-determination theory. Eastern Mediterranean Health Journal, 2020, 26, 1331-1338.	0.8	3
212	Changes in leukocyte subpopulations with decline in glomerular filtration rate in patients with type 2 diabetes. Acta Medica Iranica, 2015, 53, 425-31.	0.8	3
213	Effects of Pentoxifylline on Serum Markers of Diabetic Nephropathy in TypeÂ2 Diabetes. Diabetes Therapy, 2022, 13, 1023-1036.	2.5	3
214	Positive Correlation of Serum Adiponectin with Lipid Profile in Patients with Type 2 Diabetes Mellitus is Affected by Metabolic Syndrome Status. Archives of Iranian Medicine, 2016, 19, 269-74.	0.6	3
215	Comment on Sharif et al. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 2016;39:1424â€“1430. Diabetes Care, 2016, 39, e189-e189.	8.6	2
216	Changing correlations among ADMA, NO and hs-CRP in normoalbuminuric and microalbuminuric patients with type 2 diabetes. Meta Gene, 2016, 10, 95-99.	0.6	2

#	Article	IF	Citations
217	Prediction Of Relapse From Hyperthyroidism Following Antithyroid Medication Withdrawal Using Technetium Thyroid Uptake Scanning. Endocrine Practice, 2017, 23, 466-470.	2.1	2
218	Inadequate achievement of ABC goals (HbA1c, blood pressure, LDL-C) among patients with type 2 diabetes in an Iranian population, 2012â€"2017. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 619-625.	3.6	2
219	GABRIC Diabetes School: an innovative education centre for people with diabetes. Eastern Mediterranean Health Journal, 2018, 24, 99-103.	0.8	2
220	Combination of Angiotensin Converting Enzyme Insertion/Deletion (I/D) (rs4646994) and VEGF Polymorphism (+405G/C; rs2010963) Synergistically Associated With the Development, of Albuminuria in Iranian Patients With Type 2 Diabetes. Iranian Red Crescent Medical Journal, 2015, 17, e19469.	0.5	2
221	Comparing the Predictive Ability of Prognostic Models in Ischemic Stroke; Derivation, Validation, and Discrimination Beyond the ROC Curve. Frontiers in Neurology, 2014, 5, 9.	2.4	1
222	Pulse pressure does not predict the response of diabetic nephropathy to glucose-lowering therapy. Diabetes and Vascular Disease Research, 2015, 12, 150-151.	2.0	1
223	Serum irisin levels in metabolically healthy versus metabolically unhealthy obesity: A case-control study. Medical Journal of the Islamic Republic of Iran, 2020, 34, 46.	0.9	1
224	Quality of care in type 2 diabetes in Iran; a cross-sectional study using patient-level data. BMC Endocrine Disorders, 2022, 22, 133.	2.2	1
225	Apolipoproteins A-I and B As Components of Metabolic Syndrome with Respect to Diabetes Status: A Factor Analysis. Metabolic Syndrome and Related Disorders, 2012, 10, 280-285.	1.3	0
226	Authorsâ€™ reply. Journal of Cardiology, 2015, 65, 440.	1.9	0
227	Folate therapy improves the stress-to-rest mean LV volume ratio in myocardial perfusion imaging in patients with diabetes. Annals of Nuclear Medicine, 2015, 29, 740-744.	2.2	0
228	Relationship Between Neuropathy with Pressure on Foot in Diabetic Patients. Biosciences, Biotechnology Research Asia, 2015, 12, 57-62.	0.5	0
229	Depression Improvement Among Patients with HIV and Endocrine Dysfunction After hormone Therapy. Iranian Red Crescent Medical Journal, 2017, 19, .	0.5	0
230	Gender difference in plasminogen activator inhibitor-1 activity in patients with type 2 diabetes with and without albuminuria, a matched case-control study. Functional Foods in Health and Disease, 2019, 9, 484.	0.6	0
231	Leptin, hs-CRP and HOMA-IR in patients with type 2 diabetes: The role of different levels of vitamin D deficiency. Functional Foods in Health and Disease, 2019, 9, 695.	0.6	0
232	Association between visit-to-visit variability of glycemic indices and lipid profile and the incidence of coronary heart disease in adults with type 2 diabetes. Journal of Diabetes and Metabolic Disorders, 2021, 20, 1715-1723.	1.9	0
233	GABRIC Diabetes School: an innovative education centre for people with diabetes. Eastern Mediterranean Health Journal, 2018, 24, 99-103.	0.8	0
234	Loss of Inverse Association between Framingham Risk Score and Estimated Glomerular Filtration Rate in Moderate to Severe Diabetic Kidney Disease. Archives of Iranian Medicine, 2019, 22, 91-98.	0.6	0

#	Article	IF	Citations
235	Response to the letter to the editor concerning the manuscript, â€œUncontrolled hypertension in patients with type 2 diabetes: What are the correlatesâ€• Journal of Clinical Hypertension, 2022, 24, 662-662.	2.0	0
236	Serum osteoprotegerin in relation to metabolic status, severity, and estimated risk of subsequent coronary heart disease. Archives of Iranian Medicine, 2014, 17, 596-601.	0.6	0
237	The challenge of tuberculosis diagnosis and management in the era of the COVID-19 pandemic and diabetes mellitus. Archives of Clinical Infectious Diseases, 2022, 16, .	0.2	0